Efficacy of Proanthocyanidins in Non-Surgical Periodontal Therapy
Primary Purpose
Periodontitis, Adult
Status
Completed
Phase
Phase 2
Locations
Lithuania
Study Type
Interventional
Intervention
Minimally invasive non-surgical therapy
Subgingival application of collagen hydrogels with proanthocyanidins
Collection of saliva samples
Sponsored by
About this trial
This is an interventional treatment trial for Periodontitis, Adult
Eligibility Criteria
Inclusion criteria:
- patients with stage III and IV periodontitis with slow or moderate rate of progression (A/B) (radiographic bone loss extending to middle or apical third of the root, tooth loss due to periodontitis, maximum probing depth≥6mm, horizontal and vertical (≥3mm) bone loss);
- systemically healthy individuals;
- have≥ 20 remaining teeth;
- ≥30 years patients.
Exclusion criteria:
- patients with stage I and II periodontitis (radiographic bone loss in coronal third, no tooth loss due to periodontitis, maximum probing depth ≤5mm, mostly horizontal bone loss);
- patients with systemic diseases;
- had antibiotic therapy during the last 3 months;
- had periodontal treatment during last 6 months;
- were pregnant or lactating women;
- claimed to be allergic to the adjunct (proanthocyanidins).
Sites / Locations
- Lithuanian University of Health Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
MINST group
MINST+PACNs group
Arm Description
Patients with periodontitis received minimally invasive non-surgical therapy .
Patients with periodontitis received minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with proanthocyanidins.
Outcomes
Primary Outcome Measures
Mean PPD change from baseline in moderate sites at 8 weeks
Pocket probing depth is measured with periodontal probe. Pocket probing depth from gingival margin to the bottom of periodontal pocket.
Secondary Outcome Measures
Mean PPD change from baseline in deep sites at 8 week
Pocket probing depth is measured with periodontal probe. Pocket probing depth from gingival margin to the bottom of periodontal pocket.
Mean CAL changes from baseline at 8 week
Clinical attachment level is measured with periodontal probe.
Mean PI changes from baseline at 8 week
Presence or absence of plaque is measured.
Mean BOP change from baseline in deep sites at 8 week
Presence or absence of bleeding during periodontal probing.
Mean MMP-3, TIMP-1 changes from baseline at 8 week
Biomarkers MMP-3 (matrix metalloproteinase-3) and TIMP-1 (endogenous tissue inhibitors of metalloproteinases-1) concentration in salivary samples.
Full Information
NCT ID
NCT05015387
First Posted
August 11, 2021
Last Updated
June 24, 2022
Sponsor
Lithuanian University of Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT05015387
Brief Title
Efficacy of Proanthocyanidins in Non-Surgical Periodontal Therapy
Official Title
Efficacy of Proanthocyanidins in Non-Surgical Periodontal Therapy: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
January 9, 2019 (Actual)
Primary Completion Date
April 9, 2019 (Actual)
Study Completion Date
May 9, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Lithuanian University of Health Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The aim of the study is to evaluate the efficacy of proanthocyanidins as an adjunctive periodontal therapy in patients with periodontitis. Recently proanthocyanidins were proposed as a viable adjunct to periodontal treatment. Preclinical studies have shown high antibacterial and anti-inflammatory capacities of proanthocyanidins, that could reduce periodontal inflammation and promote periodontal tissues regeneration. In addition, proanthocyanidins demonstrate a specific antibacterial characteristic to attack periodonto-pathogenic bacteria (Porphyromonas gingivalis) but save the oral commensal bacteria (Streptococcus salivarius). Patients with periodontitis (stage III-IV) were included in this study. Patients with periodontitis received two different treatment modalities: minimally invasive non-surgical therapy only (MINST group) or minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with proanthocyanidins (MINST+PACNs group). Clinical periodontal parameters (PPD, CAL, BOP, PI) were evaluated before treatment and after 8 weeks. Concentrations of immunological markers MMP-3 and TIMP-1 in saliva were investigated.
Detailed Description
Ethical permission was issued by the Regional Biomedical Research Ethics Committee (No. BE-2-38). All included patients must have signed an informed consent form, were willing and able to show up for follow-up appointments and agreed to coded data collection. Patients were given enough time to analyze protocol of the study and were free to exit the study at any time without a specific reason. The study was performed according to CONSORT guidelines for randomized controlled clinical trials.
Patients with periodontitis (stage III-IV) were included in the study. The inclusion criteria in treatment groups were systemically healthy patients with stage III and IV periodontitis with slow or moderate rate of progression (A/B) (radiographic bone loss extending to middle or apical third of the root, tooth loss due to periodontitis, maximum probing depth≥6mm, horizontal and vertical (≥3mm) bone loss).
All patients were allocated by the Examiner 1 to two groups: the first group received minimally invasive non-surgical therapy only (MINST group), the second group- minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with PACNs (MINST+PACNs group). The same Examiner 1 performed the coding and randomization of the participants in the treatment groups with a computer-generated randomization table.
Clinical trial protocol included several appointments. At the baseline all patients received periodontal examination by periodontist (Examiner 2), the collection of saliva samples was performed. Both groups received full-mouth minimally invasive non-surgical therapy procedure by single periodontist (Examiner 2). During the MINST procedure the periodontist (Examiner 2) was not informed about the patient 's assignment to the group (MINST or MINST+PACNs). After the procedure patient 's allocation to the group was revealed to periodontist by Examiner 1 and accordingly the patient received adjunctive treatment (in MINST+PACNs group received collagen hydrogel chips with proanthocyanidins) or ended the procedure without adjunctive therapy (MINST group). Postoperative care instructions were given (no flossing or use of chemical control materials).
After the procedure patients returned for the next appointment (8 weeks after baseline). Periodontal reevaluation of encoded patients was performed by a single periodontist (Examiner 2). Saliva sample were collected in the same manner as mentioned before.
The relationship of clinical periodontal parameters and MMP-3 and TIMP-1 levels were analyzed to assess the efficacy of proanthocyanidins in periodontal therapy.
The statistical analysis was performed with IBM SPSS 28 (Armonk, NY: IBM Corp.) statistic software package. Shapiro-Wilk test was performed to assess if clinical periodontal measures (per-patient PPD, CAL, BOP and PI) and biochemical measures (MMP-3 and TIMP-1 concentrations in saliva) followed a normal distribution. Accordingly, if the data followed a normal distribution, paired-samples t-test was done to obtain before and after treatment comparisons within the groups. If the assumption of normality was violated, related samples Wilcoxon signed ranks test was done to obtain before and after treatment comparisons within the groups. The between group comparisons of measures were determined by either independent samples t-test in case the specific measure followed a normal distribution or Mann-Whitney test in case the specific measure followed a non-normal distribution. The statistical significance level was considered at the 0.05 level.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontitis, Adult
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
All patients were allocated by the same examiner to two groups: the first group received minimally invasive non-surgical therapy only (MINST group), the second group- minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with PACNs (MINST+PACNs group). The same examiner performed the coding and randomization of the participants in the treatment groups with a computer-generated randomization table.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
All patients were allocated by the Examiner 1. The same examiner performed the coding and randomization of the participants in the treatment groups with a computer-generated randomization table. Both groups received full-mouth minimally invasive non-surgical therapy procedure by single periodontist (Examiner 2), and patients in MINST+PACNs group received collagen hydrogel chips with proanthocyanidins, placed subgingivally in periodontal pockets with PPD≥4mm. After minimally invasive non-surgical therapy patients returned for the next appointment (8 weeks after baseline). Periodontal reevaluation of encoded patients was performed by a single periodontist (Examiner 2).
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MINST group
Arm Type
Active Comparator
Arm Description
Patients with periodontitis received minimally invasive non-surgical therapy .
Arm Title
MINST+PACNs group
Arm Type
Experimental
Arm Description
Patients with periodontitis received minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with proanthocyanidins.
Intervention Type
Procedure
Intervention Name(s)
Minimally invasive non-surgical therapy
Intervention Description
Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.
Intervention Type
Combination Product
Intervention Name(s)
Subgingival application of collagen hydrogels with proanthocyanidins
Intervention Description
Patients received collagen hydrogel chips with proanthocyanidins from Pelargonium sidoides root extract, placed subgingivally in periodontal pockets with PPD≥4mm after minimally invasive non-surgical therapy.
Intervention Type
Diagnostic Test
Intervention Name(s)
Collection of saliva samples
Intervention Description
For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.
Primary Outcome Measure Information:
Title
Mean PPD change from baseline in moderate sites at 8 weeks
Description
Pocket probing depth is measured with periodontal probe. Pocket probing depth from gingival margin to the bottom of periodontal pocket.
Time Frame
Before treatment and 8 weeks after baseline
Secondary Outcome Measure Information:
Title
Mean PPD change from baseline in deep sites at 8 week
Description
Pocket probing depth is measured with periodontal probe. Pocket probing depth from gingival margin to the bottom of periodontal pocket.
Time Frame
Before treatment and 8 weeks after baseline
Title
Mean CAL changes from baseline at 8 week
Description
Clinical attachment level is measured with periodontal probe.
Time Frame
Before treatment and 8 weeks after baseline
Title
Mean PI changes from baseline at 8 week
Description
Presence or absence of plaque is measured.
Time Frame
Before treatment and 8 weeks after baseline
Title
Mean BOP change from baseline in deep sites at 8 week
Description
Presence or absence of bleeding during periodontal probing.
Time Frame
Before treatment and 8 weeks after baseline
Title
Mean MMP-3, TIMP-1 changes from baseline at 8 week
Description
Biomarkers MMP-3 (matrix metalloproteinase-3) and TIMP-1 (endogenous tissue inhibitors of metalloproteinases-1) concentration in salivary samples.
Time Frame
Before treatment and 8 weeks after baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria:
patients with stage III and IV periodontitis with slow or moderate rate of progression (A/B) (radiographic bone loss extending to middle or apical third of the root, tooth loss due to periodontitis, maximum probing depth≥6mm, horizontal and vertical (≥3mm) bone loss);
systemically healthy individuals;
have≥ 20 remaining teeth;
≥30 years patients.
Exclusion criteria:
patients with stage I and II periodontitis (radiographic bone loss in coronal third, no tooth loss due to periodontitis, maximum probing depth ≤5mm, mostly horizontal bone loss);
patients with systemic diseases;
had antibiotic therapy during the last 3 months;
had periodontal treatment during last 6 months;
were pregnant or lactating women;
claimed to be allergic to the adjunct (proanthocyanidins).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nijolė Savickienė, PhD
Organizational Affiliation
Lithuanian University of Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lithuanian University of Health Sciences
City
Kaunas
ZIP/Postal Code
LT-50161
Country
Lithuania
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29926952
Citation
Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontol. 2018 Jun;89 Suppl 1:S159-S172. doi: 10.1002/JPER.18-0006. Erratum In: J Periodontol. 2018 Dec;89(12):1475.
Results Reference
background
PubMed Identifier
20335313
Citation
Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010 Jun 1;152(11):726-32. doi: 10.7326/0003-4819-152-11-201006010-00232. Epub 2010 Mar 24.
Results Reference
background
PubMed Identifier
31752295
Citation
Jekabsone A, Sile I, Cochis A, Makrecka-Kuka M, Laucaityte G, Makarova E, Rimondini L, Bernotiene R, Raudone L, Vedlugaite E, Baniene R, Smalinskiene A, Savickiene N, Dambrova M. Investigation of Antibacterial and Antiinflammatory Activities of Proanthocyanidins from Pelargonium sidoides DC Root Extract. Nutrients. 2019 Nov 19;11(11):2829. doi: 10.3390/nu11112829.
Results Reference
background
PubMed Identifier
30135370
Citation
Savickiene N, Jekabsone A, Raudone L, Abdelgeliel AS, Cochis A, Rimondini L, Makarova E, Grinberga S, Pugovics O, Dambrova M, Pacauskiene IM, Baseviciene N, Viskelis P. Efficacy of Proanthocyanidins from Pelargonium sidoides Root Extract in Reducing P. gingivalis Viability While Preserving Oral Commensal S. salivarius. Materials (Basel). 2018 Aug 22;11(9):1499. doi: 10.3390/ma11091499.
Results Reference
background
Learn more about this trial
Efficacy of Proanthocyanidins in Non-Surgical Periodontal Therapy
We'll reach out to this number within 24 hrs